Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14810466 | 0.98 | CHRM2 (0.44) | CHRM2CHRM4CHRM1CHRM3HRH3 | |
| SCHEMBL12774163 | 0.85 | SCN1A (0.44) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL4472530 | 0.84 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3HRH3 | |
| SCHEMBL26135680 | 0.82 | BCHE (0.40) | CHRM2CHRM4CHRM1CHRM3HRH3 | |
| SCHEMBL137825 | 0.79 | — | — | |
| SCHEMBL5031403 | 0.78 | HRH3 (0.40) | HRH3MEN1ALDH1A1KMT2A | |
| SCHEMBL27940840 | 0.78 | NAAA (0.49) | HRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3954088 | 0.77 | HRH3 (0.40) | HRH3MEN1KMT2A | |
| SCHEMBL1331414 | 0.75 | SCN1A (0.51) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL29090727 | 0.75 | CHRM2 (0.42) | CHRM2CHRM4CHRM1CHRM3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636335-B2 | Heteroaryl compounds as 5-HT4 receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2017-05-02 | — | — | US | disclosed |
| CN-103380131-B | As the heteroaryl compound of 5-HT4 receptors ligand | SUVEN LIFE SCIENCES LTD. (IN) | 2015-12-02 | — | — | CN | disclosed |
| US-20150283125-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-10-08 | — | — | US | disclosed |
| US-9079894-B2 | Heteroaryl compounds as 5-HT4 receptor ligands | SUVEN LIFE SCIENCES LTD (IN) | 2015-07-14 | — | — | US | disclosed |
| EP-2758394-B1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-02-18 | — | — | EP | disclosed |
| EP-2758394-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | Suven Life Sciences Limited (IN) | 2014-07-30 | — | — | EP | disclosed |
| US-20140187581-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-07-03 | — | — | US | disclosed |
| CN-103380131-A | Heteroaryl compounds as 5-ht4 receptor ligands | SUVEN LIFE SCIENCES LTD | 2013-10-30 | — | — | CN | disclosed |
| WO-2013042135-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283125-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | HTR4, HTR5A, HTR2C | CHRM2 400/4885CHRM4 190/4885CHRM1 403/4885 |
| US-20140187581-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | HTR4, HTR5A, HTR2C | CHRM2 400/4885CHRM4 190/4885CHRM1 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.